1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
  5. > Dyslipidemia Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014

SUMMARY
DelveInsight’s, “ Dyslipidemia- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014”, report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the indication. A key objective of the report is to establish the understanding for API Manufacturers for marketed and Phase III pipeline drugs across the different countries and regions. While the leading brands, companies and chemicals are considered thoroughly, the report also provides details on the drug master filings across the US, Europe and Asia specifically China and India. The research, analysis also presents the global sales forecasts data till 2015. The report is also giving insight about the patent and exclusivity details of all the drugs across the indication.

Data Sources

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight team of industry experts.

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope:
- A snapshot of the global Market therapeutics scenario for Dyslipidemia.
- A review of the marketed products under prescription for Dyslipidemia, regulatory information and marketing status.
- Coverage of global patent coverage and detailed commentaries on the US patent challenges.
- Graphical representation of investigational products for patent expiry and market exclusivities across the globe.
- Product profiles for marketed products for Dyslipidemia with complete description of mechanism of action, therapeutic class, target, route(s) of administration and chemical details.
- Coverage of API Manufacturers for Dyslipidemia drugs in the United States, Europe and Asian Regions with location details.
- Coverage of Regulatory filings in the US, Europe, and Asia specifically India and China for Dyslipidemia drugs.
- Coverage of Route of Synthesis of Active Pharmaceutical Ingredient associated with Dyslipidemia drugs.
- Coverage of Dyslipidemia Phase III pipeline products featuring sections on product description, mechanism of action, Chemical details and research & development progress.
- Coverage of the United States Drug Master File (US DMF) available for Phase III Pipeline Drugs.
- Key discontinued Marketed products.
- Global Sales Figure from 2011-2015.

Reasons to buy
- Evaluate the marketing status and exclusivity details of Dyslipidemia key products to exploit opportunities for generic drug development opportunities.
- Identify and understand important and diverse types of therapeutics under Phase III development for Dyslipidemia.
- Design effective counter-strategies to gain competitive advantage by identifying the key patent expiry details and exclusivity with respect to Dyslipidemia.
- API intelligence over marketed drugs for Dyslipidemia and gaining primary intelligence over active ingredients manufacturers across the globe.
- API intelligence over leading Phase III pipeline drugs.
- Develop and designstrategies by identifying the API manufacturers for Phase III pipeline products to enhance and expand business potential and scope.
- Understanding the scope of the Phase III Drugs with nil regulatory filings.
- Understanding the chemical route of synthesis of approved drugs for Dyslipidemia.
- Uncovering opportunities in the rapidly growing the US markets.

Table Of Contents

Dyslipidemia Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014
Table of Contents
- Indication Overview
- Marketed Drugs Assessment
- Marketed Details of Drugs by Application Type
- Marketed Details of Drugs (NDA) by Marketing Status
- Marketed Details of Drugs by Patent Expiration Timeline
- The Active Pharmaceutical Ingredient (API) Manufacturers Assessment
- The API Manufacturers by the United States Drug Master File (US DMF) Status
- The API Manufacturers by the US DMF Status (Drug Specific)
- The Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipeline Drugs
- The API Manufacturers by the US DMF Status (Drug Specific)
- Drugs Market Data and Forecasted Sales Figures (2011-2015)
- Marketed Drugs Information
- Drugs Description
- Route of Synthesis
- Global Active Pharmaceutical Manufacturers
- Approval Status
- Patent and Exclusivity Details
- Company Overview
- Phase III Drugs Information
- Phase III Drugs Description
- The United States Drug Master Filings (US DMF)
- Discontinued Drugs Information


List of Tables

Dyslipidemia Therapeutic Market, US, Marketed Drugs by Application Type, 2014
Dyslipidemia Therapeutic Market, US, Marketed Drugs by Marketing Status, 2014
Dyslipidemia Therapeutic Market, US, (Year), 2014
Dyslipidemia Marketed Drugs, API Manufacturers by US DMF Status, 2014
Dyslipidemia Marketed Drugs, US DMF Status Drug Specific (Number), 2014
Dyslipidemia Phase III Pipeline Drugs, US DMF Status Drug Specific (Number), 2014
Dyslipidemia Therapeutic Market, Global Sales (in million USD), 2014
Dyslipidemia Marketed Drugs, API Manufacturers, Global, 2014
Dyslipidemia Phase III Pipeline Drugs, United States Drug Master File (DMF), 2014
Discontinued Drugs for Dyslipidemia, 2014?


List of Figures

Dyslipidemia Therapeutic Market, US, Marketed Drugs by Application Type (%), 2014
Dyslipidemia Therapeutic Market, US, Marketed Drugs by Marketing Status (%), 2014
Dyslipidemia Therapeutic Market, US, (Year), 2014
Dyslipidemia Marketed Drugs, API Manufacturers by US DMF Status (%), 2014
Dyslipidemia Marketed Drugs, US DMF Status Drug Specific (Number), 2014
Dyslipidemia Phase III Pipeline Drugs, US DMF Status Drug Specific (Number), 2014
Dyslipidemia Therapeutic Market, Global Sales (in million USD), 2014
Dyslipidemia Marketed Drugs, Patent/Exclusivity Expiry (Year), 2014

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...

Global Markets for Diabetes Therapeutics and Diagnostics

Global Markets for Diabetes Therapeutics and Diagnostics

  • $ 6650
  • Industry report
  • September 2016
  • by BCC Research

Use this report to: - Analyze the market for drugs used in the treatment of diabetes, it's technology and the industry as a whole - Identify important trends and provide sales forecasts by product categories ...

Personal Mobility Devices Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023

Personal Mobility Devices Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023

  • $ 5795
  • Industry report
  • August 2016
  • by Transparency Market Research

Personal mobility devices such as wheelchairs, mobility scooters, and stair lifts have witnessed significant growth in revenue and volume in the past few years. A personal mobility device is either a manual ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.